glp 1 gip triple agonist Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset parkinson's disease triple agonist glp-1
Description
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
doi: 10.3389/fendo.2023.1121303 [DOI] [PMC free article] [PubMed] [Google Scholar] 28
The new retatrutide study is a phase 3 clinical trialthe gold standard needed to secure eventual FDA approvalcalled TRIUMPH-1
Tecilazich F, Dinh T, Pradhan-Nabzdyk L, Leal E, Tellechea A, Kafanas A, et al
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Preclinical Evidence Animal studies demonstrate reproductive toxicity, including skeletal and visceral abnormalities, dose-dependent growth restriction, and embryonic death
